Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

On May 31, 2022 Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, reported that it will host an investor event during the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting (Press release, Legend Biotech, MAY 31, 2022, View Source [SID1234615293]). Taking place on Sunday, June 5 at 6pm Central Time, the meeting will feature Dr. Sundar Jagannath, Professor of Medicine, Hematology and Medical Oncology at Mount Sinai School of Medicine and Director of the Multiple Myeloma Program at Mount Sinai Hospital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Jagannath will detail new and updated data from the CARTITUDE Clinical Development Program for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being studied for the treatment of patients with relapsed or refractory multiple myeloma. The meeting will follow the oral and poster presentations of the studies at the ASCO (Free ASCO Whitepaper) Annual Meeting.

Investors who are unable to join the event in person can also access it virtually by visiting Events and Presentations on the Legend Biotech website.

Arcus Biosciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

On May 31, 2022 Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, reported that its management team will participate in a fireside chat at the upcoming Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, California (Press release, Arcus Biosciences, MAY 31, 2022, View Source [SID1234615292]). The fireside chat will take place on Thursday, June 16th, 2022 at 9:20 a.m. PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available by visiting the "Investors & Media" section of the Arcus Biosciences website at www.arcusbio.com. A replay of the webcast will be available following the live event.

GRAIL Announces Collaboration With U.S. Department of Veterans Affairs and the Veterans Health Foundation to Evaluate Galleri® Multi-Cancer Early Detection Test

On May 31, 2022 GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, reported a collaboration with the U.S. Department of Veterans Affairs (VA) Veterans Health Administration, America’s largest integrated health care system, and the Veterans Health Foundation to provide Galleri, GRAIL’s groundbreaking multi-cancer early detection (MCED) blood test, to 10,000 veterans across approximately 10 participating VA sites over the next three years (Press release, Grail, MAY 31, 2022, View Source [SID1234615289]). The VA Pittsburgh Healthcare System is the first VA site that will be participating.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through the collaboration, eligible U.S. military veterans will be able to receive the Galleri test and can enroll in GRAIL’s REFLECTION registry, an observational, multi-center, real-world evidence study. REFLECTION will assess Galleri’s performance, when combined with recommended cancer screenings, to find earlier cancer in the population, when there is a higher chance of successful and potentially curative treatment. REFLECTION will enroll 35,000 healthy volunteers and evaluate the performance of Galleri in diverse clinical settings as part of routine medical care.

"Cancer is a significant issue for U.S. veterans, many of whom are at high risk," said Dr. Charles Atwood, pulmonologist and lead researcher on the REFLECTION study at VA Pittsburgh. "GRAIL’s multi-cancer early detection test will be provided to veterans, in addition to current recommended screenings, with the aim of improving early diagnoses and outcomes."

The Galleri test is a first-of-its-kind MCED blood test. In a clinical study, the Galleri test demonstrated the ability to detect signals across more than 50 types of cancers, over 45 of which lack recommended screening tests today. Using advanced genomics and machine learning, the test also determines the origin of the cancer signal, which can then guide diagnostic workup. Early detection of cancer is known to improve cancer outcomes, yet today, the majority of cancers are detected in late stages because only five cancer types have recommended screenings – breast, cervical, colon, lung and prostate cancers.

"As the largest national integrated health system in the U.S., the VA delivers unparalleled care to our veterans, many of whom are at elevated risk of developing cancer. We are thrilled to collaborate with the VA, the Veterans Health Foundation and U.S. veterans for this important real-world evaluation of the Galleri test and its potential to transform early cancer detection," said Bob Ragusa, chief executive officer at GRAIL. "Together, we hope participation in the REFLECTION registry study and receiving a Galleri test will lead to more cancer diagnoses at an earlier stage, when treatment is more likely to be successful."

Nationwide, 1.2 million veterans who have used VA health care since the beginning of fiscal year 2021 have received a cancer diagnosis. That number includes 14 percent of veterans treated at VA Pittsburgh in the same time frame.

About VA Pittsburgh Healthcare System

VA Pittsburgh Healthcare System (VAPHS) is one of the largest and most progressive VA health care systems in the nation. More than 4,000 employees serve nearly 80,000 veterans every year, providing a range of services from complex transplant medicine to routine primary care. VAPHS is a leader in virtual care delivery through telehealth technology; a center of research and learning with 130 research investigators and $14.8 million in funding in fiscal year 2021; and a provider of state-of-the-art healthcare training to some 1,500 student trainees annually. VAPHS provides care at medical centers in Pittsburgh’s Oakland neighborhood and nearby O’Hara Township, both in Pennsylvania, and five outpatient clinics in Belmont County, Ohio, and Beaver, Fayette, Washington and Westmoreland counties in Pennsylvania. An additional site of care is expected to open in Monroeville, Pennsylvania, in 2023. Veterans can call 412-360-6162 to check eligibility or enrollment. Stay up to date at pittsburgh.va.gov, Facebook and Twitter.

Lucence Showcases Promising Data on ctDNA and ctRNA Liquid Biopsy Assay for Lung Cancer at 2022 ASCO Annual Meeting

On May 31, 2022 Lucence, the precision oncology company pioneering ultrasensitive liquid biopsy tests using circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA), reported that it will present promising new data on the extension of its amplicon-based next generation sequencing (NGS) assays to new applications at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in-person in Chicago, from June 3rd to June 7th, 2022 (Press release, Lucence, MAY 31, 2022, View Source [SID1234615288]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Lucence strives to provide clinicians with the most clinically actionable information to impact patient care using liquid biopsy. The data we are presenting at 2022 ASCO (Free ASCO Whitepaper) shows how a total nucleic acid approach combining ctDNA and ctRNA in one liquid biopsy assay could dramatically increase actionable molecular information in lung cancer patients," said Min-Han Tan, PhD, MBBS, Founding CEO of Lucence.

In an abstract to be presented (#3040) as part of the conference poster sessions, Lucence CTO Yukti Choudhury and collaborators examined combining an amplicon-based NGS ctRNA assay with a ctDNA assay for enhanced detection of clinically actionable gene fusions in lung cancer when compared with ctDNA alone. In plasma samples from non-small cell lung cancer (NSCLC) patients that were either baseline driver-negative (by ctDNA) or treated with tyrosine kinase-inhibitors, the combined assay found 8.7% (9/103) more actionable fusions than ctDNA alone. Together ctRNA and ctDNA resulted in detection of 30 fusions compared to 21 when only ctDNA was tested, representing a 42.8% (9/21) increase in fusion-specific detection of the combined assay; additional fusions detected included BRAF, MET and NRG1 fusions. The data support combining ctRNA with ctDNA in liquid biopsy to increase the total actionable diagnostic information in NSCLC patients where tissue samples are lacking, especially for gene fusions not amenable to detection in ctDNA.

Lucence Research Scientist Jonathan Poh and collaborators will present data (#3042) showing that ctDNA can be utilized to non-invasively assess loss of heterozygosity (LOH) in multiple cancer types. LOH is a key biomarker to identify homologous recombination deficiency (HRD) status and predict response to PARP inhibitors. Using this approach, Poh et al. showed concordance of HRD status with an orthogonal test at 91.3%. Even in the absence of pathogenic HR gene alterations, LOH detection in ctDNA provided additional diagnostic yield of HRD+ status in multiple cancer types.

In another abstract authored by Choudhury and collaborators (#3041), analysis showed that it was possible to derive meaningful ctDNA fragment size information from a multiplexed amplicon-based assay. Several groups have shown analyzing ctDNA fragment size and ratios might be used to identify and characterize early stage cancers. Choudhury hopes to extend these so-called "fragmentomics" signatures to LiquidHALLMARK.

Lucence will be exhibiting at booth 16112 at the ASCO (Free ASCO Whitepaper) Annual Meeting. For the latest information on Lucence at 2022 ASCO (Free ASCO Whitepaper), please visit View Source

Poster Presentation Details

Yukti Choudhury, et al. A cell-free RNA-based next-generation sequencing (NGS) assay for the detection of actionable gene fusions in non-small cell lung cancer (NSCLC) patients
Poster Session: Sunday, June 5th from 8am-11am CDT

Jonathan Poh, et al. Detection of homologous recombination deficiency (HRD) in cell-free DNA (cfDNA) using an amplicon-based next-generation sequencing (NGS) assay
Poster Session: Sunday, June 5th from 8am-11am CDT

Yukti Choudhury, et al. Early detection of cancer using cell-free DNA (cfDNA) size analysis on a multiplexed amplicon-based next-generation sequencing (NGS) platform
Poster Session: Sunday, June 5th from 8am-11am CDT

Oncomatryx Announces FDA and AEMPS IND Clearance for OMTX705, a First-in-class Tumor Microenvironment-targeted ADC, to Treat Advanced Solid Tumors

On May 31, 2022 Oncomatryx reported that the FDA and the Spanish Drug Agency (AEMPS) have cleared its investigational new drug (IND) application for OMTX705, a First-in-Class antibody-drug conjugate (ADC) targeting the tumor microenvironment (Press release, Oncomatryx, MAY 31, 2022, View Source [SID1234615287]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OMTX705 is a pioneering ADC that targets, with a novel, dual mechanism of action, the Cancer-Associated Fibroblasts that enable tumor metastasis, drug resistance and immunosuppression.

OMTX705 has already shown unbeatable safety in non-human primates and tumor regression in murine models of pancreatic, breast, lung and gastric cancer.

Oncomatryx will run a multicenter, dose escalation trial in patients suffering metastatic solid tumors. OMTX705 will be administered as single agent and in combination with immunotherapy.

OMTX705 phase I clinical trial will be run in seven hospitals in USA and Spain.